Bixiye
P57-24 MagellanRx Management, a Prime Therapeutics Company (UM) Program: Medical Drug Updates
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1511 - 1520 ee natiijooyinka 3287
Bixiye
2024 September Bulletins
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
P45R1-24 Updated Reimbursement Policies, Effective September 3, 2024
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
P55-24 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
Antiretroviral - Commercial
Quantity Limit
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2024
Bixiye
Antiretroviral - Medicaid
Quantity Limit
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2024
Bixiye
Egrifta (tesamorelin) - Medicaid
Prior Authorization, Quantity Limit
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2024
Bixiye
Egrifta (tesamorelin) - Commercial
Prior Authorization, Quantity Limit
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2024
Bixiye
QP68-24 MHCP Pharmacy Benefit Exclusion for Kisunla™, PiaSky®, and Tecelra®
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP67-24 Commercial Pharmacy Benefit Exclusion for edaravone, Kisunla™, PiaSky®, and Tecelra®
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024